Jeremy Myung Jae Plambeck's Schedule 13G Filing for BriaCell Therapeutics Corp.

Jeremy Myung Jae Plambeck, a United States citizen, filed a Schedule 13G with the SEC regarding his beneficial ownership of BriaCell Therapeutics Corp. shares. The filing details his ownership of 4,329.72 common shares, 2,995.6 common shares issuable upon exercise of warrants, and 6,313.29 common shares issuable upon conversion of rights, totaling 13,638.61 common shares. The warrants and rights have a 10:1 conversion ratio. Plambeck certified that the securities were not acquired to influence the control of the issuer. The filing was made under Rule 13d-1(c) and includes a certification that the securities were not held for the purpose of changing or influencing the control of the issuer.